Literature DB >> 12765455

Effects of sulfonylurea hypoglycemic agents and adenosine triphosphate dependent potassium channel antagonists on ventricular arrhythmias in patients with decompensated heart failure.

Doron Aronson1, Murray A Mittleman, Andrew J Burger.   

Abstract

Hypoglycemic sulfonylureas block cardiac ATP-sensitive potassium channels (K(ATP)). The opening of these channels in cardiomyocytes can induce arrhythmias. In animal studies, sulfonylureas exert an antiarrhythmic effect on the ischemic myocardium, but data on human arrhythmic events are lacking. The study population included 207 patients (age 61 +/- 14 years) admitted for decompensated CHF. The severity of ventricular arrhythmias was assessed by 24-hour Holter monitoring. None of the patients were on parenteral vasoactive therapy or antiarrhythmics during Holter recording. Diabetic patients comprised 48% of the study population, and 34% of diabetic patients were prescribed sulfonylureas. The mean hourly ventricular pairs (3.6 +/- 0.5 vs 1.8 +/- 0.3, P = 0.03), the mean hourly repetitive ventricular beats (5.7 +/- 1.0 vs 2.6 +/- 0.1, P = 0.03), and the frequency of ventricular tachycardia episodes per 24 hours (4.7 +/- 0.8 vs 2.2 +/- 0.4, P = 0.03) were significantly lower in patients with diabetes who were receiving sulfonylureas compared with nondiabetics. No significant difference occurred between patients with diabetes who were not receiving sulfonylureas and nondiabetic patients. Multivariate regression revealed a negative independent relationship between sulfonylurea therapy and hourly ventricular pairs (P = 0.03), the mean hourly repetitive ventricular beats (P = 0.03), and ventricular tachycardia episodes (P = 0.04). In a multiple logistic regression, sulfonylurea therapy was a negative predictor of repetitive ventricular beats (P = 0.01, adjusted OR, 0.31; 95% CI, 0.12-0.78). Concomitant sulfonylurea therapy may reduce the occurrence of complex ventricular ectopy in the setting of severe CHF. These results suggest that cardiac K(ATP) channel activation may be involved in the genesis of ventricular arrhythmias in CHF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12765455     DOI: 10.1046/j.1460-9592.2003.t01-1-00177.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  10 in total

Review 1.  Mitochondria are sources of metabolic sink and arrhythmias.

Authors:  Fadi G Akar; Brian O'Rourke
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

Review 2.  Mechanisms of sudden cardiac death: oxidants and metabolism.

Authors:  Kai-Chien Yang; John W Kyle; Jonathan C Makielski; Samuel C Dudley
Journal:  Circ Res       Date:  2015-06-05       Impact factor: 17.367

Review 3.  Sulfonylureas: a new look at old therapy.

Authors:  Peter M Thulé; Guillermo Umpierrez
Journal:  Curr Diab Rep       Date:  2014-04       Impact factor: 4.810

Review 4.  Cardiac mitochondria and arrhythmias.

Authors:  David A Brown; Brian O'Rourke
Journal:  Cardiovasc Res       Date:  2010-07-09       Impact factor: 10.787

5.  Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia.

Authors:  Charles E Leonard; Colleen M Brensinger; Christina L Aquilante; Warren B Bilker; Denise M Boudreau; Rajat Deo; James H Flory; Joshua J Gagne; Margaret J Mangaali; Sean Hennessy
Journal:  Diabetes Care       Date:  2018-02-02       Impact factor: 19.112

Review 6.  Redox control of cardiac excitability.

Authors:  Nitin T Aggarwal; Jonathan C Makielski
Journal:  Antioxid Redox Signal       Date:  2012-08-16       Impact factor: 8.401

Review 7.  Mitochondria and arrhythmias.

Authors:  Kai-Chien Yang; Marcelo G Bonini; Samuel C Dudley
Journal:  Free Radic Biol Med       Date:  2014-04-05       Impact factor: 7.376

Review 8.  Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence.

Authors:  Charles E Leonard; Sean Hennessy; Xu Han; David S Siscovick; James H Flory; Rajat Deo
Journal:  Trends Endocrinol Metab       Date:  2017-05-22       Impact factor: 12.015

9.  Mitochondria and arrhythmias.

Authors:  Cody Rutledge; Samuel Dudley
Journal:  Expert Rev Cardiovasc Ther       Date:  2013-07

Review 10.  Mitochondrial Dysfunction as Substrate for Arrhythmogenic Cardiomyopathy: A Search for New Disease Mechanisms.

Authors:  Chantal J M van Opbergen; Lyanne den Braven; Mario Delmar; Toon A B van Veen
Journal:  Front Physiol       Date:  2019-12-10       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.